key: cord-0272087-783xoclv authors: Miyazato, Y.; Tsuzuki, S.; Morioka, S.; Terada, M.; Kutsuna, S.; Saito, S.; Shimanishi, Y.; Takahashi, K.; Sanada, M.; Akashi, M.; Kuge, C.; Osanai, Y.; Tanaka, K.; Suzuki, M.; Hayakawa, K.; Ohmagari, N. title: Risk factors associated with development and persistence of long COVID date: 2021-09-23 journal: nan DOI: 10.1101/2021.09.22.21263998 sha: 98c70781212dd1a61eb39af9ef1861d6aacd3a99 doc_id: 272087 cord_uid: 783xoclv Background Long COVID has been a social concern. Though patient characteristics associated with developing long COVID are partially known, those associated with persisting it have not been identified. Methods We conducted a cross-sectional questionnaire survey of patients after COVID-19 recovery who visited the National Center for Global Health and Medicine between February 2020 and March 2021. Demographic and clinical data, and the presence and duration of long COVID were obtained. We identified factors associated with development and persistence of long COVID using multivariate logistic and linear regression analysis, respectively. Results We analyzed 457 of 526 responses (response rate, 86.9%). The median age was 47 years, and 378 patients (84.4%) had mild disease in acute phase. The number of patients with any symptoms after 6 and 12 months after onset or diagnosis were 120 (26.3%) and 40 (8.8%), respectively. Women were at risk for development of fatigue (OR 2.03, 95% CI 1.31-3.14), dysosmia (OR 1.91, 95% CI 1.24-2.93), dysgeusia (OR 1.56, 95% CI 1.02-2.39), and hair loss (OR 3.00, 95% CI 1.77-5.09), and were at risk for persistence of any symptoms (coefficient 38.0, 95% CI 13.3-62.8). Younger age and low body mass index were risk factors for developing dysosmia (OR 0.96, 95% CI 0.94-0.98, and OR 0.94, 95% CI 0.89-0.99, respectively) and dysgeusia (OR 0.98, 95% CI 0.96-1.00, and OR 0.93, 95% CI 0.88-0.98, respectively). Conclusion We identified risk factors for the persistence as well as development of long COVID. Many patients suffer from long-term residual symptoms, even in mild cases. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 23, 2021. ; https://doi.org/10.1101/2021.09.22.21263998 doi: medRxiv preprint Our cross-sectional questionnaire survey of patients recovering from COVID-19 revealed that women, young age, and low body mass index were risk factors for the development of multiple symptoms, and that even mild cases of COVID-19 suffered from long-term residual symptoms. Long COVID has been a social concern. Though patient characteristics associated with developing long COVID are partially known, those associated with persisting it have not been identified. We conducted a cross-sectional questionnaire survey of patients after COVID-19 recovery who visited the National Center for Global Health and Medicine between February 2020 and March 2021. Demographic and clinical data, and the presence and duration of long COVID were obtained. We identified factors associated with development and persistence of long COVID using multivariate logistic and linear regression analysis, respectively. We analyzed 457 of 526 responses (response rate, 86.9%). The median age was 47 years, and . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 23, 2021. ; https://doi.org/10.1101/2021.09.22.21263998 doi: medRxiv preprint 5 378 patients (84.4%) had mild disease in acute phase. The number of patients with any symptoms after 6 and 12 months after onset or diagnosis were 120 (26.3%) and 40 (8.8%), respectively. Women were at risk for development of fatigue (OR 2.03, 95% CI 1.31-3.14), We identified risk factors for the persistence as well as development of long COVID. Many patients suffer from long-term residual symptoms, even in mild cases. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 23, 2021. COVID-19 has become a global threat, with 226 million infections and 4.65 million deaths worldwide as of September 16, 2021 [1] . After the onset of COVID-19, approximately 76% of patients are known to have prolonged symptoms lasting more than six months [2] known as long COVID or post-acute sequelae of SARS-CoV-2 infection (PASC). Previous studies have shown that frequent symptoms of long COVID include fatigue, dyspnea, and dysosmia, and that multiple symptoms often overlap and persist [2] [3] [4] . Some symptoms of COVID-19, such as hair loss, which were not present at the time of onset, may appear after recovery [4] . In addition, it has been reported that 5-10% of patients continue to experience moderate to severe problems at work, and in social and family life, eight months after the onset of COVID-19 [5] . The impact of long COVID on society is immeasurable. However, the characteristics of patients who are more likely to develop long COVID are only partially known [2] , and it is important to identify risk factors in order to properly understand and prevent long COVID. In this study, we explored the risk factors for the development and persistence of long COVID in a cohort of patients recovering from COVID-19 at a hospital designated for infectious diseases in Japan. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint This study was designed as a single-center, cross-sectional survey, in which a self-report questionnaire was mailed to eligible patients in April 2021 with two reminders: two weeks and one month later. Participation in this survey was voluntary, but not anonymous. The participants after COVID-19 recovery were requested to complete and return the questionnaire. Potential participants were recruited from patients who had recovered from COVID-19 and visited the outpatient service of the Disease Control and Prevention Center (DCC) in the NCGM from February 2020 to March 2021 in order to obtain a pre-donation screening test for COVID-19 convalescent plasmapheresis [6] . We developed the questionnaire through a systematic literature review with reference to similar previous studies ] [11] , findings from our previous study on . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 23, 2021. ; https://doi.org/10.1101/2021.09.22.21263998 doi: medRxiv preprint 8 prolonged and late-onset symptoms of COVID-19 [4] , and comprehensive discussions among the authors. We attempted to minimize the number of questions to maximize the response rate. The instrument was piloted on 13 patients who had recovered from COVID-19; they provided feedback on the content, clarity, and format of the items. They also confirmed that the survey questions were self-explanatory. Minor revisions were made in response to their feedback. Patient characteristics (e.g., age, sex, height, weight, smoking history, drinking history, underlying medical conditions, and obstetric history), information regarding the acute phase of COVID-19 (e.g., presence of pneumonia, disease severity; oxygen therapy/mechanical ventilation/extracorporeal membrane oxygenation: ECMO, treatment, antivirals/steroids), and presence and duration of symptoms related to COVID-19 were investigated (Appendix 1). Underlying medical conditions included hypertension, diabetes, dyslipidemia, bronchial asthma, chronic obstructive pulmonary disease (COPD), myocardial infarction, malignancies, connective tissue/rheumatic diseases, immune-deficiency disease, chronic kidney disease, and others. Disease severity was categorized as follows [2] [12]: 1) Mild: no oxygen therapy; 2) Moderate: oxygen therapy without mechanical ventilation; and 3) Severe: mechanical ventilation with or without ECMO. Symptoms related to COVID-19 were fever, fatigue, shortness of breath (SoB), . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 23, 2021. ; https://doi.org/10.1101/2021.09.22.21263998 doi: medRxiv preprint joint pain, myalgia, chest pain, cough, abdominal pain, dysosmia, dysgeusia, runny nose, conjunctivitis, headache, sputum, sore throat, diarrhea, nausea, loss of appetite, hair loss, depression, loss of concentration, and memory disturbance (MD). The patient characteristics, presence of pneumonia, disease severity, and treatment in the acute phase of COVID-19 were expressed as median, interquartile range (IQR), or % (n), where applicable. The proportion of patients with prolonged symptoms and days since the onset of COVID-19 was described. The symptoms of more than 100 participants in this study were categorized and defined as follows: 1) Acute symptoms, which resolved or did not appear within 28 days after the onset of COVID-19 in >90% of participants; 2) On-going/chronic symptoms, which did not resolve within 28 days after the onset of COVID-19 in >10% of participants; and 3) Late-onset symptoms, which appeared 28 days after the onset of COVID-19 in >5% of participants. Multivariate logistic regression analyses were performed to calculate the adjusted odds ratios (ORs) with 95% confidence intervals (CIs) for the development of on-going/chronic symptoms and late-onset symptoms. The multivariate logistic regression model was performed . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint Classification of symptoms associated with COVID-19 The number of participants experiencing symptoms associated with COVID-19, the number of participants with symptoms lasting for more than four weeks and 12 weeks, and the number of the participants whose symptoms developed more than four weeks after the onset of We classified 17 long COVID symptoms into three categories after excluding less frequent symptoms reported in less than 100 participants (chest pain, abdominal pain, runny nose, conjunctivitis, and nausea): 1) acute symptoms (e.g., fever, headache, loss of appetite, joint pain, sore throat, myalgia, diarrhea, and sputum) that persisted for four weeks in less than 10% of the participants; 2) On-going/Chronic symptoms (e.g., fatigue, dysosmia, cough, dysgeusia, shortness of breath) that persisted for four weeks in more than 10% of the participants except for late-onset symptoms; and 3) late-onset symptoms (e.g., loss of concentration, depression, hair loss, and memory disturbance), which developed more than four weeks after the onset of COVID-19 in more than 5% of the participants with the symptoms. The frequency and duration of acute symptoms, on-going/chronic symptoms, and late-onset symptoms are summarized in Appendix 3, Figure 1 and 2, respectively. A few participants reported on-going/chronic symptoms, including dysosmia (n=35, 7.7%), fatigue . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. participants (93.3%) had diffuse hair loss, and 6 participants (6.7%) had patchy hair loss. Moreover, the frequency and duration of at least one symptom are shown in Figure 3 (any symptoms included acute, on-going/chronic, and late-onset symptoms). The number of participants with at least one symptom after six months and 12 months after symptom onset or diagnosis of COVID-19 were 120 (26.3%) and 40 (8.8%), respectively. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint (Figure 4) . . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This cross-sectional questionnaire survey is one of the few studies to identify the risk factors for both development and persistence of COVID-19. We also examined the duration of long COVID in more detail by surveying participants who had recovered from COVID-19 for a median period of 248.5 days. One of the most important findings in this study was that female sex was a risk factor for developing multiple symptoms such as fatigue, dysosmia, dysgeusia, and hair loss after acute COVID-19, and were at risk for persistence of dysgeusia and any symptoms associated with COVID-19. Female sex has been recognized as a risk factor for multiple long COVID symptoms in previous studies [2] [13] [14] . In a cohort study in Wuhan, China, female sex was associated with the development of lung diffusion impairment, anxiety or depression, and fatigue or muscle weakness [2] . In addition, women are more prone to having multiple symptoms and are more likely to experience fatigue, sleep disorders, and mental symptoms [14] . Based on the previous literature [15], we believe that the effect of reporting bias that women are more likely to report symptoms than men is small. Chronic fatigue is the most frequently reported symptom following recovery from . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Another important finding in this study was that younger age and lower BMI were risk factors for dysgeusia and dysosmia. Our telephone interviews conducted in Japan also revealed that younger participants, especially those in their twenties, had a higher incidence of dysosmia . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint and dysgeusia [25] . A possible mechanism of gustatory dysfunction in COVID-19 concerns the functional link between taste and smell, whereby gustatory perception is reduced because of antecedent olfactory sensory dysfunction [26] . Long-lasting dysosmia and dysgeusia are critical issues that can affect the quality of life, even in young patients. Further research is needed to explore the pathophysiology and eventually identify treatment options. Our study revealed that majority of participants with alopecia had diffuse hair loss. Previous studies stated that majority of patients with alopecia after COVID-19 recovery were due to telogen effluvium [27] . As telogen effluvium is a noninflammatory alopecia that causes diffuse hair loss, our findings were consistent with the previous study. On the other hand, a few participants in our study had patchy hair loss. Some case reports demonstrated that alopecia areata is a possible mechanism of patchy hair loss after COVID-19 recovery [28] [29] . Lastly, the third important finding in this study was that there was little effect of antiviral medication or steroids on long COVID symptoms, except for dysosmia. The efficacy of rehabilitation has been suggested for the treatment of long COVID symptoms, but nothing has been established as effective for treatment, and the efficacy of vitamin C has also been denied [30] . Therefore, to prevent long COVID, it is important not to be infected with SARS-CoV-2. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint Our study has several limitations. First, this study relied on patient self-reports and, therefore, might have been subject to recall bias. Second, some patients reported on-going/chronic and late-onset symptoms at the time of the questionnaire survey. In these cases, . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. the actual duration of the symptoms was unclear, and it is likely that this study underestimated the duration of these symptoms. Long-term observation is needed to better understand the duration of a long COVID. Third, although a previous study indicated that severity of illness was a risk factor for developing fatigue [2] , being severe was not a risk factor for developing fatigue in this study. This is partly because most of the participants in our study were mild cases, and the number of severe cases was markedly small. Further studies are needed to clarify whether the severity of illness is a risk factor for the development and persistence of long COVID. In conclusion, our cross-sectional questionnaire survey evaluated patients after recovery from COVID-19, most of whom had mild disease, for the development and persistence of long COVID. Women were at risk for development of fatigue, dysosmia, dysgeusia, and hair loss, and were at risk for persistence of dysgeusia and any symptoms associated with COVID-19. Younger age and low BMI were found to be at risk of developing dysosmia and dysgeusia. In addition, about a quarter of the participants had at least one prolonged symptom for more than six months, indicating that many COVID-19 patients suffer from long-term residual symptoms, even in mild cases. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. COVID-19 Coronavirus Pandemic 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study Persistent Symptoms in Patients After Acute COVID-19 Prolonged and Late-Onset Symptoms of Coronavirus Disease Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers How we secured a COVID-19 convalescent plasma procurement scheme in Japan Post-acute COVID-19 syndrome Long-term Health Consequences of COVID-19 Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network -United States Neurological manifestations and complications of COVID-19: A literature review 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study Attributes and predictors of long COVID Half-year follow-up of patients recovering from severe COVID-19: 25. COVID-19 Registry Japan. Disaster Mangement, Cabinet Office Odor/taste integration and the perception of flavor SARS-CoV-2-induced telogen effluvium: a multicentric study Alopecia areata in a COVID-19 patient: A case report Alopecia areata in a patient with SARS-Cov-2 infection Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial We thank all the people who participated in our study, "Collection and antibody measurement of Convalescent plasma foreseeing the use for COVID-19 treatment". All authors report no conflicts of interest relevant to this article.. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintThe copyright holder for this this version posted September 23, 2021. ; https://doi.org/10.1101/2021.09.22.21263998 doi: medRxiv preprint